Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$31.67 USD
0.00 (0.00%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $31.67 0.00 (0.00%) 6:16 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Agios Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -352.09 | -231.80 | 1,604.72 | -327.37 | -411.47 |
Depreciation/Amortization & Depletion | 1.57 | 7.37 | 16.19 | 13.01 | 4.89 |
Net Change from Assets/Liabilities | -19.06 | -16.43 | -36.82 | -71.04 | -46.00 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | -2,054.46 | 0.00 | 0.00 |
Other Operating Activities | 73.51 | -68.61 | 63.06 | 94.64 | 81.96 |
Net Cash From Operating Activities | -296.06 | -309.48 | -407.32 | -290.76 | -370.62 |
Property & Equipment | 0.33 | -3.92 | -5.74 | -14.91 | -12.17 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 256.75 | 115.39 | -548.42 | 90.65 | 103.61 |
Other Investing Activities | -17.50 | 131.78 | 1,802.94 | 0.00 | 0.00 |
Net Cash from Investing Activities | 239.58 | 243.26 | 1,248.78 | 75.75 | 91.44 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 5.43 | 2.68 | -765.19 | 11.32 | 289.72 |
Issuance (Repayment) of Debt | 0.00 | -0.33 | -0.58 | -0.34 | -0.11 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 250.54 | 0.00 |
Net Cash from Financing Activities | 5.43 | 2.35 | -765.77 | 261.52 | 289.61 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -51.05 | -63.87 | 75.69 | 46.51 | 10.43 |
Cash at Beginning of Period | 139.26 | 203.13 | 127.44 | 80.93 | 70.50 |
Cash at End of Period | 88.21 | 139.26 | 203.13 | 127.44 | 80.93 |
Diluted Net EPS | -6.33 | -4.23 | 26.55 | -4.74 | -6.86 |
Fiscal Year End for Agios Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -352.09 | -256.15 | -164.82 | -81.02 |
Depreciation/Amortization & Depletion | NA | 1.57 | 0.56 | -2.14 | -0.99 |
Net Change from Assets/Liabilities | NA | -19.06 | -24.66 | -21.96 | -25.78 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 73.51 | 56.67 | 26.99 | 12.60 |
Net Cash From Operating Activities | NA | -296.06 | -223.57 | -161.93 | -95.18 |
Property & Equipment | NA | 0.33 | 0.56 | -0.25 | -0.25 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 256.75 | 161.00 | 104.97 | 57.85 |
Other Investing Activities | NA | -17.50 | -17.50 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 239.58 | 144.06 | 104.72 | 57.60 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 5.43 | 4.59 | 2.70 | 2.47 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 5.43 | 4.59 | 2.70 | 2.47 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -51.05 | -74.93 | -54.51 | -35.12 |
Cash at Beginning of Period | NA | 139.26 | 139.26 | 139.26 | 139.26 |
Cash at End of Period | NA | 88.21 | 64.33 | 84.75 | 104.14 |
Diluted Net EPS | NA | -1.71 | -1.64 | -1.51 | -1.47 |